CG Results is delighted to announce that it has advised Robiquity Group Limited (Robiquity) on its investment from Growth Capital Partners (“GCP”).
This transaction reinforces CG Results’ position as a leading advisor in the Automation Services sector having previously advised Horizon Capital on its investment in BP3 Global, Roboyo on its investment from MML Capital Partners and Symphony Ventures on its acquisition by SYKES Enterprises.
Robiquity is a specialist Intelligent Automation services provider with a heritage in implementing robotic process automation applications and enabling businesses to automate and scale manual processes using technology. Robiquity is one of the few leading UK independent service providers and has expertise in the financial services, consumer and telco sectors.
Robiquity was founded in 2016 by Tom Gardner and Jack Rimmer. In 2018 they evolved the business to provide a full consulting offering and in 2020 they appointed a CEO, Tom Davies. Robiquity now offers end to end support for clients from strategy through to a managed service offering.
Robiquity has grown the headcount of the business to 100 and now has operations across North America and the Middle East. The business now works with some of the leading technology vendors in the automation market and has built an impressive list of clients including Virgin Media, Finastra and AO.
GCP’s investment will support Robiquity’s ambitious plans to become a clear independent leader in the automation space, with an intention to create over 100 new technology jobs in the UK as well as drive international growth.
>>>> Read the press release here
CG Results is pleased to announce that it has acted as the exclusive financial advisor to Agile MV (the “Company”), a leading contract development and manufacturing organization focused on medical devices, on its sale to Resonetics LLC, a portfolio company of GTCR and The Carlyle Group.
Agile MV, based in Montreal, Quebec, specializes in the design and manufacture of minimally invasive medical devices, with particular expertise in electrophysiology and interventional cardiology. It counts among its clients some of the largest medical device companies in the world as well as early-stage companies seeking to develop new innovations in the sector. Since starting its operation in 2014, the Company has assisted its clients in developing products that have treated over a million patients around the world, and has grown to over 100 full-time employees, including engineers, technicians, and product builders.
The acquisition of Agile MV will enable Resonetics, a world leader in micro manufacturing, to continue its expansion of expertise across the spectrum of minimally invasive medical devices and assist in its rapid prototyping and development initiatives.
The combination of US-based Resonetics and Canadian-based Agile MV is another example of CG Results’ expertise in brokering cross-border transactions.
Pierre-Georges Roy and Jason Foss led the transaction with the close support of Matt Duff and Leo Bucksbaum in New York and Murelli Sooriyakumar in London.
CG Results is delighted to announce that it has advised Intigriti, Europe’s leading bug bounty and vulnerability disclosure platform, on its €21,133,700 Series B fundraise. This round represents the largest funding for a crowdsourced security platform in Europe to date.
The round was led by Octopus Ventures, one of Europe’s largest and most active early-stage investors. Germany-based fund EnBW New Ventures is also participating in the round, alongside previous investors and Intigriti’s largest shareholder, ETF Partners.
Intigriti’s global cybersecurity platform connects organisations with ethical hackers to continuously test and improve their security through bug bounty programs and other crowdsourced techniques. Achieving 650% growth since its initial funding round in 2020, Intigriti has established itself as the European leader and fastest-growing crowdsourced security platform globally, and some of the biggest corporate organisations are transitioning their bug bounty to the EU-based platform.
The new investment will enable Intigriti to further accelerate its rapid detection, reporting and validation of vulnerabilities. Intigriti will also use the funds to grow its headcount to more than 200 employees worldwide in the UK, Europe, and Singapore as well as investing in tools and features to strengthen its position as the platform of choice for ethical hackers.
CG Results acted as exclusive financial adviser to Intigriti, cementing its position as the most active advisor for European cybersecurity with 13 deals in the sector to date.
CG Results is thrilled to announce that it has acted as the exclusive financial advisor to Terranova Security, a market-leading cyber security awareness training SaaS platform, on its acquisition by HelpSystems, a portfolio company of TA Associates, HGGC, Charlesbank, and Harvest Partners SCF.
Terranova Security is a Gartner-recognized, global security awareness training partner whose software makes it easy to build risk-based campaigns that feature the industry’s highest-quality training content and real-world phishing simulations. Using a proven pedagogical framework, Terranova Security training solutions empower organizations worldwide to implement programs that change user behaviors, reduce the human risk factor, and counter cyber threats effectively. Available in more than 40 languages, Terranova Security’s platform and content incorporates gamification techniques to increase engagement and knowledge retention. This approach enables all organizations to hone employee cyberattack prevention skills and reduce the chance of a successful phishing attack.
The combination of these two businesses will extends HelpSystems’ overall security suite with a proven training security awareness SaaS solution that complements email security offerings from Clearswift, Agari, and PhishLabs.
This is CG Results’ second transaction in the cyber security awareness subsector, and 12th deal overall in cyber security.
Novartis has divested its sterile fill/finish facility located in Boucherville, Canada to Delpharm, a leading contract development and manufacturing organisation with 18 plants in France, Italy, Belgium, Canada, Poland and The Netherlands. The Boucherville plant will allow Delpharm to conduct sterile vial and ampoule manufacturing in North America.
This deal represents CG Results’ 7th deal advising Novartis over the past 2 years.
LONDON, 28th February 2022 – CGE Partners (“CGE”) is pleased to announce its investment in Datapharm, a leading provider of regulatory-driven medicines information and software solutions to the pharmaceutical industry. Datapharm’s core platform, the electronic medicines compendium (“emc”), is the UK’s leading source of trusted medicines information used by pharmaceutical companies, healthcare professionals and patients.
Datapharm lies at the core of the UK medicines information ecosystem, benefitting from 45 years of industry expertise and longstanding trusted relationships with customers. The business supports pharmaceutical companies in maintaining regulatory compliance and its software solutions are trusted by over 300 of the world’s top global life sciences companies. CGE is partnering with Datapharm’s management team to accelerate new product development, international expansion and strategic acquisitions.
Simon Abrams, CEO of Datapharm, commented: “We are excited to welcome CGE as our investment partner to achieve our vision of improving the accessibility and excellence of medicines information in the pharmaceutical industry. With CGE’s support, Datapharm will continue to expand its suite of best-in-class software solutions to our customers whilst maintaining its reputation for independence and trust.”
CGE Partners commented: “We are delighted to be partnering with Simon and the management team at Datapharm. Datapharm’s mission-critical solutions and commitment to patient safety and regulatory compliance strongly align with our focus on partnering with purposeful businesses that deliver a positive impact.”
Datapharm marks the sixth investment from CGE’s first fund.
>>>>> Read the press release here
CG Results Healthcare is delighted to announce that it has advised Recipharm, a top five global pharmaceutical CDMO, on the divestment of the Aesica Pharmaceuticals API manufacturing site located in Cramlington, UK, to Pharmaron.
This transaction highlights CG Results Healthcare’s excellent reputation in the healthcare and life sciences sector and is a testament to our international network. It highlights our deep sector expertise, strong buyer relationships, and outstanding track record of achieving high-value outcomes for our clients.
Recipharm is a world leading CDMO in the pharmaceutical industry, employing almost 9,000 employees across 30+ facilities in 10 countries. It offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and Active Pharmaceutical Ingredients (APIs), pharmaceutical product development as well as development and manufacturing of medical devices. The Aesica Pharmaceuticals Cramlington site near Newcastle, UK, has an established history of cGMP manufacturing services for an array of APIs. The divestment helps Recipharm streamline their operations in line with its ongoing strategy.
Pharmaron has acquired the Cramlington site to further expand its chemistry and manufacturing services and strengthen its global service network. The synergistic integration of the Cramlington site with Pharmaron’s existing service capabilities of discovery, process development and early-stage cGMP API manufacturing at Hoddesdon, will enable a complete end-to-end chemistry and manufacturing service offering in the United Kingdom.
>>>>> Read the press release here
CG Results Healthcare is thrilled to announce that it has advised Calcium USA, a market-leading, full-service healthcare marketing agency, on its significant investment from NexPhase Capital Partners, a thematic and operationally-focused private equity firm.
This transaction further solidifies Results Healthcare as the leading advisor in the healthcare commercialization and marketing sector, having now completed our 11th deal in the space since 2019. It highlights our deep sector expertise, strong buyer relationships, and outstanding track record achieving high-value outcomes for our clients.
Calcium is an award-winning, healthcare marketing agency offering a comprehensive range of leading-edge strategic, creative, and engagement capabilities—all focused on delivering robust brand nourishment and business growth for clients. Serving as a partner to many of the leading global and US pharma and biotech companies, Calcium serves as subject matter experts across the breadth of therapeutic areas, focusing on high-growth sectors, including oncology, rare disease, immunology, neuroscience, respiratory, and anti-infectives. Led by Steven Michaelson and Judy Capano, Calcium has assembled a broad, experienced leadership team of individuals with a strong track record and experience in pharma, healthcare, and in large and small networks, and continues to receive “Agency of the Year” recognitions as well as multiple awards for its creative campaigns.
Calcium has partnered with NexPhase Capital to further cement itself as a market leader in healthcare marketing. With over 125 employees and offices in Miami, New York City, Philadelphia, and San Francisco, Calcium is structured to deliver an even greater impact and value for a wider range of clients—all while maintaining a nourishing, stimulating, and supportive culture in which the people of Calcium (i.e., Calciumites) can thrive.
CG Results is delighted to announce that it has advised iController, a leading B2B SaaS provider of intelligent solutions for credit and collections management, on its acquisition by US-headquartered Billtrust (NASDAQ: BTRS).
Founded in 2007, Belgium-based iController has 566 European customers and its SaaS offering enables a wide range of users, from credit and collections managers to CFOs, to optimise credit management and improve visibility into cash flow management.
Billtrust is a B2B accounts receivable (AR) automation and integrated payments leader and this transaction is part of its global strategic expansion plan, expanding its presence in the European market and enhancing its global credit and collections capabilities
This deal emphasises our strong track-record of helping our European software clients achieve great outcomes with US acquirers and investors.